CLINICAL TRIALS PROFILE FOR RESCRIPTOR

All Clinical Trials for Rescriptor

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002210 ↗	A Study of Delavirdine Mesylate in Combination With Other Anti-HIV Drugs in HIV-Infected Children and Babies	Completed	Pharmacia and Upjohn	Phase 2	1969-12-31	The purpose of this study is to see if it is safe and effective to give delavirdine mesylate (Rescriptor) plus two nucleoside reverse transcriptase inhibitors (NRTIs) to HIV-infected children and babies. This study also examines how the body processes Rescriptor when taken with 2 NRTIs.
NCT00002211 ↗	Safety and Effectiveness of Giving Combinations of Three or Four Anti-HIV Drugs to HIV-Infected Patients	Completed	Pharmacia and Upjohn	N/A	1969-12-31	The purpose of this study is to see if it is safe and effective to give combinations of three or four anti-HIV drugs to HIV-infected patients. The drugs used in this study are delavirdine (DLV), nelfinavir (NLF), didanosine (ddI), and stavudine (d4T).
NCT00002400 ↗	A Study of Two Anti-HIV Drug Combinations in HIV-Infected Patients	Completed	Pharmacia and Upjohn	N/A	1969-12-31	The purpose of this study is to compare the safety and effectiveness of giving HIV-infected patients delavirdine (DLV) plus zidovudine (ZDV) plus 2 doses of indinavir (IDV) or ZDV plus IDV plus lamivudine (3TC). This study also examines how the body processes DLV when it is given in combination with other drugs.
NCT00002401 ↗	A Study of Delavirdine Used Together With Other Anti-HIV Drugs in HIV-Infected Patients	Completed	Pharmacia and Upjohn	N/A	1969-12-31	The purpose of this study is to see if it is safe and effective to give delavirdine (DLV) in combination with two or three other drugs to HIV-infected patients. The drugs to be used in combination with DLV are zidovudine (ZDV), indinavir (IDV), and lamivudine (3TC).
NCT00002420 ↗	The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors	Terminated	Pharmacia and Upjohn	Phase 2	1969-12-31	The purpose of this study is to see if it is safe and effective to give MKC-442, didanosine (ddI), stavudine (d4T), and delavirdine (DLV) to HIV-positive patients.
NCT00002420 ↗	The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors	Terminated	Triangle Pharmaceuticals	Phase 2	1969-12-31	The purpose of this study is to see if it is safe and effective to give MKC-442, didanosine (ddI), stavudine (d4T), and delavirdine (DLV) to HIV-positive patients.
NCT00002420 ↗	The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors	Terminated	Bristol-Myers Squibb	Phase 2	1969-12-31	The purpose of this study is to see if it is safe and effective to give MKC-442, didanosine (ddI), stavudine (d4T), and delavirdine (DLV) to HIV-positive patients.

Clinical Trial Conditions for Rescriptor

Condition Name

Condition Name for Rescriptor
Intervention	Trials
HIV Infections	6
HIV-1 Infection	1

Condition MeSH

Condition MeSH for Rescriptor
Intervention	Trials
HIV Infections	7
Acquired Immunodeficiency Syndrome	1

Clinical Trial Locations for Rescriptor

Trials by Country

Trials by Country for Rescriptor
Location	Trials
United States	9

Trials by US State

Trials by US State for Rescriptor
Location	Trials
New Jersey	4
California	2
New York	1
Missouri	1
Maryland	1

Clinical Trial Progress for Rescriptor

Clinical Trial Phase

Clinical Trial Phase for Rescriptor
Clinical Trial Phase	Trials
Phase 2/Phase 3	1
Phase 2	2
N/A	3

Clinical Trial Status

Clinical Trial Status for Rescriptor
Clinical Trial Phase	Trials
Completed	6
Terminated	1

Clinical Trial Sponsors for Rescriptor

Sponsor Name

Sponsor Name for Rescriptor
Sponsor	Trials
Pharmacia and Upjohn	5
Triangle Pharmaceuticals	1
Bristol-Myers Squibb	1

Sponsor Type

Sponsor Type for Rescriptor
Sponsor	Trials
Industry	8
NIH	2
Other	1